HomeLatest Pharma-NewsAZ's NDA filing anticipated based on positive data from interim analysis

Latest Pharma-News

AZ’s NDA filing anticipated based on positive data from interim analysis

June 22, 2022

48

Previous article

FDA Announces Plans for Proposed Rule to Reduce Addictiveness of Tobacco Products

Next article

Novartis Tabrecta receives EC approval for METex14 skipping advanced nSCLC

LEAVE A REPLY Cancel reply

Most Popular

FDA Takes Steps to Ensure Safety of Cinnamon Products Sold in the US

March 8, 2024

FDA Clears First Over-the-Counter Continuous Glucose Monitor

March 8, 2024

FDA, Industry Actions End Sales of PFAS Used in US Food Packaging

March 1, 2024

Regulatory Applications Accepted in the U.S. and Japan for BMS Breyanzi in Relapsed or Refractory FL and Relapsed or Refractory MCL

February 3, 2024

EDITOR PICKS

Job Interview Questions for Clinical Data Management 2024

August 14, 2021

CRASH COURSE ON CLINICAL DATA MANAGEMENT

November 24, 2020

Interview Questions on Institutional Review Board(IRB)

August 27, 2020

POPULAR POSTS

How to Find Paid Clinical Trials Near You

January 2, 2023

What Is CDISC and What Are CDISC Data Standards?

May 17, 2022

What is Dechallenge, Rechallenge and Prechallenge in Clinical trials?

August 5, 2021

ABOUT US

LifeProNow provides guidance and high quality contents to help job seekers to get their dream Job. All the contents are written by experienced folks and peer reviewed by experts.

Contact us: [email protected]

FOLLOW US

© LifeProNow | All Rights Reserved